CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 138 enrolled
Drug / intervention
Interferon α-2bbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00749684
NCT00749684N/ACompleted
CompareCT.gov

Efficacy and Safety of High-dose Treatment With the Immunomodulator Interferon-α-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma.

Merck Sharp & Dohme LLC·observational·Posted Sep 9, 2008·Updated Oct 19, 2015

In Brief

An observational study evaluating Interferon α-2b for Melanoma. Completed, enrolled 138 participants.

Detailed Summary

The aim of this observational study is to document the efficacy and tolerability of high-dose interferon therapy in adult participants with malignant melanoma at high risk of relapse and to compare them with the survival times and relapse rates in previous studies (historical control).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
Countries--
Collaborators--

Timeline

N/ACompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 9, 2008
Enrollment StartDec 1, 1996
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 12.8 yearsPosted 17.8 years ago

Interventions

Interferon α-2bbiological

20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.